{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:43:01Z","timestamp":1762659781089,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00277-019-03633-x","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T03:24:03Z","timestamp":1550892243000},"page":"1159-1168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-7243","authenticated-orcid":false,"given":"Stephanie","family":"Dulucq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Chollet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Robbesyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Turcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Tigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,23]]},"reference":[{"key":"3633_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"3633_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"3633_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","volume":"2017","author":"F-X Mahon","year":"2017","unstructured":"Mahon F-X (2017) Treatment-free remission in CML: who, how, and why? Hematol Am Soc Hematol Educ Program 2017:102\u2013109. \n                    https:\/\/doi.org\/10.1182\/asheducation-2017.1.102","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3633_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, Sandin F, H\u00f6glund M, Stenke L, Bj\u00f6rkholm M, Lambe M, Olsson-Str\u00f6mberg U, Richter J, Sj\u00e4lander A (2016) Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol 97:387\u2013392. \n                    https:\/\/doi.org\/10.1111\/ejh.12743","journal-title":"Eur J Haematol"},{"key":"3633_CR5","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, on behalf of the IRIS investigators (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood 116:3758\u20133765. \n                    https:\/\/doi.org\/10.1182\/blood-2010-03-273979","journal-title":"Blood"},{"key":"3633_CR6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102. \n                    https:\/\/doi.org\/10.1038\/leu.2012.85","journal-title":"Leukemia"},{"key":"3633_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232\u2013238. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.6565","journal-title":"J Clin Oncol"},{"key":"3633_CR8","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O\u2019Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J (2013) Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121:4867\u20134874. \n                    https:\/\/doi.org\/10.1182\/blood-2013-03-490128","journal-title":"Blood"},{"key":"3633_CR9","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, M\u00fcller MC (2012) Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 30:4323\u20134329. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.40.5217","journal-title":"J Clin Oncol"},{"key":"3633_CR10","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O\u2019Brien S, Clark R, Goldman J, Marin D (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121:2739\u20132742. \n                    https:\/\/doi.org\/10.1182\/blood-2012-11-466037","journal-title":"Blood"},{"key":"3633_CR11","first-page":"3993","volume":"122","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Choi S, Kantarjian HM et al (2013) Relative ratio of BCR-ABL1 transcript clearance improves the prognostic value of single PCR assessment at the 3 and 6 month time points in patients with chronic myeloid leukemia in chronic phase treated in the DASISION study. Abstract ASH 2013 Blood 122:3993","journal-title":"Abstract ASH 2013 Blood"},{"key":"3633_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ajh.23707","volume":"89","author":"D Kim","year":"2014","unstructured":"Kim D (Dong H, Hamad N, Lee HG, et al (2014) BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol 89:626\u2013632 . doi: \n                    https:\/\/doi.org\/10.1002\/ajh.23707","journal-title":"Am J Hematol"},{"key":"3633_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP (2014) Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124:511\u2013518. \n                    https:\/\/doi.org\/10.1182\/blood-2014-03-566323","journal-title":"Blood"},{"key":"3633_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, de Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353\u20131360. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-510396","journal-title":"Blood"},{"key":"3633_CR15","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","volume":"124","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, Lutz P, Verite C, Berthou C, Galambrun C, Sirvent N, Yakouben K, Schmitt C, Gandemer V, Reguerre Y, Couillault G, Mechinaud F, Cayuela JM (2014) Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 124:2408\u20132410. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-578567","journal-title":"Blood"},{"key":"3633_CR16","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M et al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28:1988\u20131992. \n                    https:\/\/doi.org\/10.1038\/leu.2014.153","journal-title":"Leukemia"},{"key":"3633_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvilli\u00e9 L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69\u201381. \n                    https:\/\/doi.org\/10.1111\/bjh.13108","journal-title":"Br J Haematol"},{"key":"3633_CR18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3109\/10428194.2014.974047","volume":"56","author":"C Boquimpani","year":"2015","unstructured":"Boquimpani C, Schaffel R, Biasoli I, Bendit I, Spector N (2015) Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leuk Lymphoma 56:1787\u20131792. \n                    https:\/\/doi.org\/10.3109\/10428194.2014.974047","journal-title":"Leuk Lymphoma"},{"key":"3633_CR19","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34:2333\u20132340. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"3633_CR20","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.clml.2016.03.008","volume":"16","author":"C Fava","year":"2016","unstructured":"Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G (2016) Early BCR-ABL1 reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor. Clin Lymphoma Myeloma Leuk 16(Suppl):S96\u2013S100. \n                    https:\/\/doi.org\/10.1016\/j.clml.2016.03.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3633_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.11622\/smedj.2016063","volume":"58","author":"PC Bee","year":"2017","unstructured":"Bee PC, Sekaran V, Ng RRJ, Kweh TY, Gan GG (2017) The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country. Singap Med J 58:150\u2013154. \n                    https:\/\/doi.org\/10.11622\/smedj.2016063","journal-title":"Singap Med J"},{"key":"3633_CR22","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1080\/10428194.2016.1239260","volume":"58","author":"Y-Z Qin","year":"2017","unstructured":"Qin Y-Z, Jiang Q, Lai Y-Y, Jiang H, Shi HX, Zhao XS, Liu YR, Huang XJ (2017) Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma 58:1384\u20131393. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1239260","journal-title":"Leuk Lymphoma"},{"key":"3633_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O\u2019Brien S (2012) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120:291\u2013294. \n                    https:\/\/doi.org\/10.1182\/blood-2012-01-407486","journal-title":"Blood"},{"key":"3633_CR24","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818\u20133824. \n                    https:\/\/doi.org\/10.1182\/blood-2012-10-462291","journal-title":"Blood"},{"key":"3633_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-511592","journal-title":"Blood"},{"key":"3633_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00432-017-2445-z","volume":"143","author":"JL Steegmann","year":"2017","unstructured":"Steegmann JL, Colomer D, G\u00f3mez-Casares M-T, Garc\u00eda-Guti\u00e9rrez V, Ort\u00ed G, Ram\u00edrez-Payer A, Olavarria E, Vall-llovera F, Giraldo P, Conde E, Vallansot R, L\u00f3pez-Lorenzo JL, Palomera L, \u00c1lvarez-Larr\u00e1n A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF (2017) An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol 143:2059\u20132066. \n                    https:\/\/doi.org\/10.1007\/s00432-017-2445-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"3633_CR27","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. \n                    https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"3633_CR28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang L, Pearson K, Ferguson JE, Clark RE (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120:990\u2013999","journal-title":"Br J Haematol"},{"key":"3633_CR29","first-page":"816","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Ross DM et al (2014) The adverse effect of high Sokal risk for first line Imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Abstract ASH 2014 Blood 124:816\u2013816","journal-title":"Abstract ASH 2014 Blood"},{"key":"3633_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H (2015) Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol 90:282\u2013287. \n                    https:\/\/doi.org\/10.1002\/ajh.23923","journal-title":"Am J Hematol"},{"key":"3633_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106250","volume":"9","author":"S Huet","year":"2014","unstructured":"Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F (2014) Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended. PLoS One 9:e106250. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0106250","journal-title":"PLoS One"},{"key":"3633_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","volume":"22","author":"NCP Cross","year":"2009","unstructured":"Cross NCP (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22:355\u2013365. \n                    https:\/\/doi.org\/10.1016\/j.beha.2009.04.001","journal-title":"Best Pract Res Clin Haematol"},{"key":"3633_CR33","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cav\u00e9 H, Pane F, Aerts JLE, de Micheli D, Thirion X, Pradel V, Gonz\u00e1lez M, Viehmann S, Malec M, Saglio G, van Dongen JJM (2003) Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 17:2318\u20132357. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2403135","journal-title":"Leukemia"},{"key":"3633_CR34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, M\u00fcller MC, Hochhaus A (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999\u20131003. \n                    https:\/\/doi.org\/10.1038\/leu.2015.29","journal-title":"Leukemia"},{"key":"3633_CR35","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues J-F, Jacqmin-Gadda H (2013) Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32:5381\u20135397. \n                    https:\/\/doi.org\/10.1002\/sim.5958","journal-title":"Stat Med"},{"key":"3633_CR36","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","volume":"119","author":"J Guilhot","year":"2012","unstructured":"Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R (2012) Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 119:5963\u20135971. \n                    https:\/\/doi.org\/10.1182\/blood-2011-10-383711","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03633-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T19:37:09Z","timestamp":1582400229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03633-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03633-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2019,2,23]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Clinical and laboratory data are recorded CCTIRS N\u00b0: 14.251 and CNIL N\u00b0: 915088.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FXM, FN, and GE declare partnerships with Bristol-Myers Squibb, Incyte, Novartis, and Pfizer in support of educational, clinical, or scientific activities.SD declares partnerships with Bristol-Myers Squibb, Incyte, and Novartis in support of educational or scientific activities.SH, IT, EK, FR, CC, and BT declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}